| scholarly article | Q13442814 |
| P50 | author | Karen L Kotloff | Q63214788 |
| P2093 | author name string | Levine MM | |
| Sansonetti PJ | |||
| Losonsky GA | |||
| Sztein MB | |||
| Picking WD | |||
| Samandari T | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Shigella dysenteriae | Q265094 |
| P304 | page(s) | 2221-2232 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain | |
| P478 | volume | 164 |
| Q47205506 | A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. |
| Q64996406 | A murine model of diarrhea, growth impairment and metabolic disturbances with Shigella flexneri infection and the role of zinc deficiency. |
| Q37120727 | Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates |
| Q34809879 | Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. |
| Q34669980 | Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics |
| Q35805439 | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| Q35729793 | Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q40939427 | Controlling the cytokine storm in severe bacterial diarrhoea with an oral Toll-like receptor 4 antagonist |
| Q91641168 | Development of Silica-Immobilized Vaccines for Improving Thermo-Tolerance and Shelf-Life |
| Q40552716 | Development of recombinant vaccine candidate molecule against Shigella infection |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q45711236 | Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q28972559 | Immunology of Gut Mucosal Vaccines |
| Q39517102 | Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q91705205 | Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model |
| Q34006071 | Parameters underlying successful protection with live attenuated mutants in experimental shigellosis |
| Q46799503 | Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. |
| Q34120926 | Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults |
| Q41008205 | Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q59809065 | Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: Results of a Phase 2, randomized, double-blind placebo-controlled trial |
| Q30369367 | Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. |
| Q64244181 | Screening for coeliac disease in children and adults living in a slum of Dhaka, Bangladesh |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q34003433 | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q52657631 | T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. |
Search more.